Squarepoint
ATYR

Squarepoint’s aTyr Pharma ATYR Stock Holding History

Squarepoint’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-124,924
Closed -$90.1K – 5024
2025
Q3 		$90.1K Buy
+124,924
New +$566K ﹤0.01% 4132
2025
Q2 		– Sell
-235,242
Closed -$710K – 5179
2025
Q1 		$710K Buy
235,242
+208,628
+784% +$761K ﹤0.01% 2965
2024
Q4 		$96.3K Buy
26,614
+13,233
+99% +$40.1K ﹤0.01% 4703
2024
Q3 		$23.6K Buy
+13,381
New +$24.3K ﹤0.01% 4014
2024
Q1 		– Sell
-119,450
Closed -$168K – 4711
2023
Q4 		$168K Sell
119,450
-20,540
-15% -$26.3K ﹤0.01% 3657
2023
Q3 		$221K Sell
139,990
-19,369
-12% -$35.8K ﹤0.01% 3353
2023
Q2 		$344K Buy
159,359
+147,185
+1,209% +$321K ﹤0.01% 2881
2023
Q1 		$25.6K Buy
+12,174
New +$26.7K ﹤0.01% 3112
2016
Q3 		– Sell
-886
Closed -$34K – 1300
2016
Q2 		$34K Buy
+886
New +$41.2K ﹤0.01% 1046

Other funds holding ATYR

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Squarepoint's ATYR Position: Q4 2025 in Review

Squarepoint sold out of aTyr Pharma (ATYR) in Q4 2025, closing a stake of 124,924 shares — an estimated $90.1K sold.

Squarepoint first reported a position in ATYR in Q2 2016 and held it in 9 quarters. The position peaked at $710K in Q1 2025. 84 funds tracked by Wall St. Rank hold ATYR as of Q4 2025.

  • Squarepoint reported no remaining aTyr Pharma position as of Q4 2025 after selling out during the quarter.
  • Squarepoint sold 124,924 aTyr Pharma shares in Q4 2025, an estimated $90.1K.
  • Squarepoint first reported a position in aTyr Pharma in Q2 2016 and held it in 9 quarters.
  • Squarepoint's aTyr Pharma position peaked at $710K in Q1 2025.
  • 84 funds tracked by Wall St. Rank held aTyr Pharma as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.